Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2021, specifically reporting on an announcement issued on December 20, 2021. The filing details a regulatory milestone for ViiV Healthcare, a global specialist HIV company majority-owned by GSK (with Pfizer and Shionogi as shareholders). The core subject is the US Food and Drug Administration (FDA) approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV pre-exposure prophylaxis (PrEP).
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: This filing is a regulatory announcement regarding product approval and does not contain financial statements. Consequently, the text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for GSK or ViiV Healthcare.
Material Changes and Clinical Data
While financial changes are not reported, the filing details significant clinical and regulatory developments:
- Regulatory Approval: The FDA approved Apretude for use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV.
- Efficacy Superiority: In the HPTN 083 and HPTN 084 trials involving over 7,700 participants, Apretude demonstrated superior efficacy compared to daily oral PrEP (FTC/TDF tablets).
- HPTN 083 (Men who have sex with men and transgender women): 69% lower incidence of HIV compared to oral tablets.
- HPTN 084 (Cisgender women): 90% lower incidence of HIV compared to oral tablets.
- Dosing Regimen: The medication is administered as an injection as few as six times per year (every two months after an initiation phase), offering an alternative to daily oral medication.
Outlook, Risks, and Management Commentary
Management Commentary and Outlook: ViiV Healthcare CEO Deborah Waterhouse emphasized the importance of this approval for Black and Latinx communities disproportionately impacted by HIV, noting that the trial included diverse populations. The company plans to begin shipping Apretude to US wholesalers and specialty distributors in early 2022 and has initiated submissions to other regulatory authorities. However, the filing notes that Apretude has not yet been approved outside the US for HIV prevention.
Risks and Contingencies: The filing includes a boxed warning regarding the risk of drug resistance if Apretude is used by individuals with undiagnosed HIV-1 infection. Key risks and precautions include:
- Drug Resistance: Individuals must test negative for HIV-1 prior to initiation and before each subsequent injection.
- Adverse Reactions: Common reactions (observed in at least 1% of participants) include injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, and dizziness.
- Discontinuation Rates: Adverse events led to discontinuation in 6% of participants in HPTN 083 and 1% in HPTN 084.
- Residual Concentrations: Cabotegravir may remain in the systemic circulation for up to 12 months or longer after discontinuation.
- Contraindications: Includes unknown or positive HIV-1 status, previous hypersensitivity to cabotegravir, and coadministration with drugs that significantly decrease cabotegravir plasma concentrations.
Investor Verification Checklist
- Verify the commercial launch timeline and initial sales projections for Apretude in the US market for early 2022.
- Monitor the status of regulatory submissions to authorities outside the US, as approval is currently limited to the US for PrEP.
- Assess the competitive landscape for HIV PrEP, specifically the market share impact of a long-acting injectable versus daily oral options.
- Review the full prescribing information for detailed drug interaction profiles and long-term safety data.
- Confirm the specific revenue contribution of ViiV Healthcare to GSK's overall portfolio in subsequent quarterly reports.